Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Dan Sherbenou, MD, PhD, received an American Cancer Society grant to study resistance to three key treatments for a blood cancer.
Researchers looking at ovarian cancer cells that resist chemotherapy hope to develop new therapeutic strategies.
In early experiments, researchers found that “the antibiotics [could] buy the precious time needed for immunotherapy to kick in.”
A new study shines light on one cause of resistance to androgen receptor-targeting drugs.
A study shows how “epigenetic” changes can lead to the development of certain cancers, and how to short-circuit the cancer-causing machine...
“To understand cancer better, we need the combination of chemistry, biology, chemical biology, computational biology and bioinformatics.”
The findings hold particular promise for people who haven’t been helped by the targeted drug tagraxofusp.
Acquired resistance has sent many researchers back to the lab in an effort to uncover its cause, and new tools that may help to overcome it.
Several studies focused on this topic were recently reported on at the AACR-Melanoma Conference.
HIV, anti-vaxxers, dengue fever and weak primary health care make the World Health Organization’s list of priorities.
The discovery points the way toward a new strategy for precision cancer therapy.
In tumors with missing or mutated BRCA genes, PARP inhibitors plus other drugs have worked well—but the cancer often becomes drug-resistant.
Dietary or drug interventions could counteract resistance to PI3K inhibitors in many tumors.
This finding could lead to clinical trials specifically for men with treatment-emergent small-cell neuroendocrine prostate cancer.
Treatment-resistant cancers self-destruct when exposed to experimental drug.
The cells’ immediate response was to change the mechanisms they use to evade treatment and start dividing again—in just a few days.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.